Neurocrine Biosciences(NBIX) Stock Price Today

US Stock MarketDetailed Quotes

NBIX Neurocrine Biosciences

Watchlist

107.240
+0.780+0.73%

Close Apr 29 16:00 ET

107.010
-0.230-0.21%

Post 17:14 ET

10.61BMarket Cap32.60P/E (TTM)

Post-Market

5D
Daily
Weekly
Monthly
1Q
1Y

Trade Overview

Unit: --

Capital Trend

IntradayDayWeekMonth

No Data

News

BofA Securities Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Maintains Target Price $179
Moomoo NewsApr 29 03:33 ET · Ratings
CCORF Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $158
Moomoo NewsApr 29 03:33 ET · Ratings
Neurocrine Biosciences (NBIX) Q1 Earnings Preview: What's in the Cards?
Yahoo FinanceApr 28 10:00 ET
Neurocrine Price Target Cut to $158.00/Share From $163.00 by Canaccord Genuity
Dow JonesApr 28 07:59 ET · Ratings
Neurocrine Is Maintained at Buy by Canaccord Genuity
Dow JonesApr 28 07:59 ET · Ratings
Evercore Maintains Neurocrine Biosciences(NBIX.US) With Buy Rating, Cuts Target Price to $185
Moomoo NewsApr 25 04:32 ET · Ratings

Comments

Teddy123

Mar 31 20:35

Neurocrine Biosciences Presents Real-World Data on Therapeutic Dose Attainment and Dosing Trends of VMAT2 Inhibitors in Patients With Tardive Dyskinesia

$Neurocrine Biosciences (NBIX.US)$
New Data: INGREZZA Outperforms Competitors with Perfect Therapeutic Dose Rate

Teddy123

Mar 20 20:44

Neurocrine Biosciences Presents 48-Week Remission Data on Treatment of Tardive Dyskinesia With INGREZZA® (valbenazine) Capsules

$Neurocrine Biosciences (NBIX.US)$
Breakthrough: INGREZZA Achieves 59% Remission in Tardive Dyskinesia Patients Over 48 Weeks

Teddy123

Mar 17 20:38

Neurocrine Biosciences Presents New KINECT®-HD Data Showing Significant Reduction in Chorea Across Body Regions With INGREZZA® (valbenazine) Capsules

$Neurocrine Biosciences (NBIX.US)$
Breakthrough: INGREZZA Phase 3 Data Reveals Powerful Chorea Control Across All Body Regions

Teddy123

Mar 5 21:51

Neurocrine Biosciences Announces Initiation of Phase 1 Clinical Study Evaluating NBI-1140675, a Second-Generation VMAT2 Inhibitor, in Healthy Adults

$Neurocrine Biosciences (NBIX.US)$
Can Neurocrine's New VMAT2 Inhibitor Replicate Its Previous FDA Success? Phase 1 Trial Launches

Kevin Travers

Feb 8 05:05

Columns Wall Street Today: One More Earnings Week Down

Overall, the market traded lower Friday, after a week of trade and earnings upsets.
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ traded down 0.95%, the $Dow Jones Industrial Average (.DJI.US)$ fell 0.99%, and the $Nasdaq Composite Index (.IXIC.US)$ fell 1.36%.
MACRO
Macroeconomic news might have swayed the market as jobs and unemployment data came in. The economy added 143,000 jobs in January, according to the BLS, which was low, but N...